These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31570241)

  • 1. Review of von Willebrand Disease and Acquired von Willebrand Syndrome for Patients Undergoing Cardiac Surgery.
    Berger J; Schwartz J; Ramachandran S; Leff JD
    J Cardiothorac Vasc Anesth; 2019 Dec; 33(12):3446-3457. PubMed ID: 31570241
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients.
    Mazzeffi M; Henderson R; Krause E; Rabin J; Madathil R; Chow J; Grazioli A; Meyer M; Wu Z; Tanaka K
    Anesth Analg; 2022 Feb; 134(2):312-321. PubMed ID: 34903705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of von Willebrand factor and factor VIII after elective heart surgery in a 12-year-old girl with von Willebrand disease type 3.
    Kühne T; Imbach P; Marbet GA; Caliezi C; Devay J
    Pediatr Hematol Oncol; 1999; 16(6):551-6. PubMed ID: 10599096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis of von Willebrand disease.
    Roberts JC; Flood VH
    Int J Lab Hematol; 2015 May; 37 Suppl 1(Suppl 1):11-7. PubMed ID: 25976955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.
    Miesbach W; Berntorp E
    Eur J Haematol; 2017 Feb; 98(2):121-127. PubMed ID: 27622750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between VWF and FVIII in treating VWD.
    Miesbach W; Berntorp E
    Eur J Haematol; 2015 Nov; 95(5):449-54. PubMed ID: 25605439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
    Mohammed S; Favaloro EJ
    Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Course of von Willebrand Factor and Factor VIII Activity in Patients with von Willebrand Disease during Pregnancy.
    Delbrück C; Miesbach W
    Acta Haematol; 2019; 142(2):71-78. PubMed ID: 31085919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of von Willebrand Disease.
    Curnow J; Pasalic L; Favaloro EJ
    Semin Thromb Hemost; 2016 Mar; 42(2):133-46. PubMed ID: 26838696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.
    Favaloro EJ
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):553-64. PubMed ID: 21885953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What have we learned from large population studies of von Willebrand disease?
    Montgomery RR; Flood VH
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):670-677. PubMed ID: 27913545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
    Lubetsky A; Martinowitz U; Luboshitz J; Kenet G; Keller N; Tamarin I; Inbal A
    Haemophilia; 2002 Sep; 8(5):622-8. PubMed ID: 12199669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.